DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
Company profile
Ticker
DXCM
Exchange
Website
CEO
Kevin Sayer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
SweetSpot Diabetes Care, Inc. • TypeZero Technologies, Inc. • DexCapital, LLC • The Glucose Program, LLC • Nintamed Handels GmbH • DexCom Canada, Co. • DexCom Deutschland GmbH • DexCom (Malayisa) Sdn Bhd. • DexCom Philippines, Inc. • DexCom Asia Pacific Operations PTE Ltd. ...
IRS number
330857544
DXCM stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
9 Feb 23
8-K
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
9 Feb 23
8-K
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
9 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Dexcom Reports Third Quarter 2022 Financial Results
27 Oct 22
8-K
Departure of Directors or Certain Officers
31 Aug 22
8-K
Other Events
5 Aug 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
8-K
Other Events
28 Jul 22
8-K
Dexcom Reports Second Quarter 2022 Financial Results
28 Jul 22
Transcripts
DXCM
Earnings call transcript
2022 Q4
9 Feb 23
DXCM
Earnings call transcript
2022 Q3
27 Oct 22
DXCM
Earnings call transcript
2022 Q2
29 Jul 22
DXCM
Earnings call transcript
2022 Q1
29 Apr 22
DXCM
Earnings call transcript
2021 Q4
11 Feb 22
DXCM
Earnings call transcript
2021 Q3
29 Oct 21
DXCM
Earnings call transcript
2021 Q2
30 Jul 21
DXCM
Earnings call transcript
2021 Q1
29 Apr 21
DXCM
Earnings call transcript
2020 Q4
12 Feb 21
DXCM
Earnings call transcript
2020 Q3
27 Oct 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 643.30 mm | 643.30 mm | 643.30 mm | 643.30 mm | 643.30 mm | 643.30 mm |
| Cash burn (monthly) | 18.60 mm | 34.19 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 54.49 mm | 100.17 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 588.81 mm | 543.13 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 31.7 | 15.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 887 |
| Opened positions | 169 |
| Closed positions | 57 |
| Increased positions | 317 |
| Reduced positions | 307 |
| 13F shares | Current |
|---|---|
| Total value | 41.71 tn |
| Total shares | 368.90 mm |
| Total puts | 4.29 mm |
| Total calls | 4.37 mm |
| Total put/call ratio | 1.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 43.82 mm | $4.96 tn |
| BLK Blackrock | 33.19 mm | $3.76 tn |
| Baillie Gifford & Co | 17.30 mm | $1.96 tn |
| STT State Street | 16.45 mm | $1.86 tn |
| Sands Capital Management | 15.51 mm | $1.75 tn |
| FMR | 10.95 mm | $1.24 tn |
| JPM JPMorgan Chase & Co. | 10.65 mm | $1.20 tn |
| Capital Research Global Investors | 9.46 mm | $1.07 tn |
| Jennison Associates | 9.19 mm | $1.04 tn |
| Geode Capital Management | 8.11 mm | $916.95 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Mar 23 | Pacelli Steven Robert | Common Stock | Sell | Dispose S | No | Yes | 116.4 | 5,442 | 633.45 k | 138,129 |
| 16 Mar 23 | Matthew Vincent Dolan | Common Stock | Sell | Dispose S | No | Yes | 115 | 2,303 | 264.85 k | 33,569 |
| 14 Mar 23 | Sadie Stern | Common Stock | Sell | Dispose S | No | Yes | 111.86 | 393 | 43.96 k | 83,645 |
| 10 Mar 23 | Balo Andrew K | Common Stock | Sale back to company | Dispose D | No | No | 111.399 | 5,990 | 667.28 k | 50,908 |
| 10 Mar 23 | Balo Andrew K | Common Stock | Sale back to company | Dispose D | No | No | 111.399 | 2,405 | 267.91 k | 56,898 |
| 10 Mar 23 | Balo Andrew K | Common Stock | Sale back to company | Dispose D | No | No | 111.399 | 3,275 | 364.83 k | 59,303 |
| 10 Mar 23 | Abbey Donald | Common Stock | Sale back to company | Dispose D | No | No | 111.399 | 3,390 | 377.64 k | 208,023 |
| 10 Mar 23 | Abbey Donald | Common Stock | Sale back to company | Dispose D | No | No | 111.399 | 4,675 | 520.79 k | 211,413 |
| 10 Mar 23 | Abbey Donald | Common Stock | Sale back to company | Dispose D | No | No | 111.399 | 3,604 | 401.48 k | 216,088 |
News
Price Over Earnings Overview: DexCom
23 Mar 23
10 Health Care Stocks Whale Activity In Today's Session
16 Mar 23
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,900 Today
15 Mar 23
(DXCM) - Analyzing DexCom's Short Interest
6 Mar 23
Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years
2 Mar 23
Press releases
Continuous Glucose Monitoring Systems Market Size is Likely to Grow US$ 9.56 Billion by 2027 At a CAGR 9.50%
21 Mar 23
DexCom Comments on SVB Relationship
13 Mar 23
What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?
28 Feb 23
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
13 Feb 23
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
9 Feb 23